What is Pexidartinib?

Pexidartinib is an inhibitor of multiple receptor tyrosine kinases including colony-stimulating factor 1 receptor (CSF-1R), c-Kit proto-oncogene protein (c-Kit) and FMS-like tyrosine kinase -3 (Flt-3). It is an anti-tumor agent. Pexidartinib is indicated for the treatment of adult patients with symptomatic giant cell tumor of the tendon sheath (also known as giant cell tumor of the tendon sheath[GCT-TS] or pigmented villonodular synovitis [PVNS]) who are associated with significant morbidity or functional limitations that cannot be improved with surgery. Pesidartinib has been designated as an orphan drug by the U.S. Food and Drug Administration (FDA) for the treatment of this disease.

Pesidartinib works by inhibiting the growth of tenosynovial giant cell tumors. In clinical trials including patients with symptomatic giant cell tumors of the tenosynovium, pexidartinib was associated with higher overall response rates compared with placebo, characterized by improved patient symptoms and functional outcomes. Pesidartinib works by inhibiting the activation and signaling of tumor-permissive cytokines and receptor tyrosine kinases, which play important roles in tumor cell proliferation and survival. Taking pesidartinib with a high-fat meal may increase the incidence and severity of adverse reactions, including hepatotoxicity, Advise patients to take pexidartinib at least1 hour before or after eating a meal or snack. Common side effects include hair color change, fatigue, eye swelling, rash, and taste disturbance.

There is less information on the price of pexidartinib after it is launched. For more drug information and specific prices, please consult the medical consultant.